Epitalon reference dosing
epitalon dosage> Updated:
Calculate the Epitalon dose
The calculator is already set up for Epitalon — adjust the dose or diluent volume for your vial.
In short
Epitalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly from the Khavinson bioregulator group. Described regimens are short courses of subcutaneous injections: 5–10 mg per day over 10–20 days (or 10 mg × 10 days), repeated 2–3 times a year. Continuous daily use is not described for it: the pause between courses is part of the schedule.
Human dosing
Epitalon dosing in the schedule below is always tied to a short course, 10–20 consecutive days, rather than continuous daily use, reflecting the logic of peptide bioregulators built for short-term action rather than a steady blood level.
| Period / condition | Dose | Escalation |
|---|---|---|
| Course, 10–20 consecutive days | 5–10 mg per day subcutaneously | Primary regimen |
| Shorter intensive course | 10 mg per day × 10 days | Alternative option |
| Course repetition | 2–3 times per year | Maintenance, if needed |
Practical dosing and effect details
Epitalon, the synthetic tetrapeptide Ala-Glu-Asp-Gly, is used in research and clinical protocols in courses rather than continuously. Just four amino acids in the chain mean fast enzymatic breakdown in blood, so daily injections through the course maintain a short, repeated concentration peak rather than a steady level. That logic is shared across the Khavinson-group peptide bioregulators: a short course of daily injections is meant to trigger a short-term effect, while continuous use is neither described nor the protocol's goal.
The schedule on this page, 5–10 mg per day over 10–20 days, or a shorter intensive course of 10 mg times 10 days, repeated 2–3 times a year, reflects that same course logic: the pause between courses is as much a part of the regimen as the dose itself. The dose is set for a specific experiment, so the figures above are a reference point from described protocols, not a fixed standard.
This is reference information on regimens from published sources, not a medical recommendation.
Frequently asked questions
Does epitalon come as a spray or tablets? Such forms appear in shops, but the described protocols cover subcutaneous injections: no regimens with verified bioavailability have been published for sprays or tablets. The schedule on this page is about the injectable form only.
How do I reconstitute a 10 mg vial, and how many syringe units is that? A typical example: 10 mg reconstituted with 2 ml of bacteriostatic water gives 5 mg/ml. Then a 5 mg daily dose is 1 ml, or 100 units on a U-100 syringe, and the intensive 10 mg regimen is the whole vial per day. A different water volume means a different concentration; the reconstitution calculator gives the exact figure.
Why is epitalon used in courses rather than continuously? That is the logic of peptide bioregulators: a short course of daily injections is built for a short-term effect, not for holding a steady blood level. The pause between courses is therefore as much a part of the regimen as the dose itself.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 10 mg vial.Epitalon10 mg+ 2 mlDiluent
- 2Get the concentrationExample: 10 mg in 2 ml =Epitalon5 mg/ml(5,000 mcg/ml)
- 3Work out the volume per doseFor example, for a 5 mg dose:5 mg = 1 ml= 100 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
Epitalon: reference regimens
Epitalon (the tetrapeptide Ala-Glu-Asp-Gly) is administered subcutaneously in short courses across research and clinical protocols.
More scientific background in the Epitalon monograph
Notes and safety
- • Epitalon is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
